The Indian pharmaceutical sector experienced a significant 8.8% growth in FY26, reaching an impressive Rs 2.46 lakh crore, predominantly driven by the cardiac and anti-diabetic segments. Key players such as Sun Pharma, Abbott, Cipla, Mankind, and Torrent Pharma reported double-digit growth. Notably, Eli Lilly's Mounjaro emerged as a top seller in drug sales during this period.

Mankind Pharma conducted a significant block deal worth INR 52.6 crore, selling 251,668 shares at approximately INR 2,088 per share on the National Stock Exchange.

Analysts suggest investing in Adani Power, Titan, Cummins India, Mankind Pharmaceuticals, and Arvind Ltd, due to their positive technical trends and sectoral performance. Expected price levels for these stocks are Rs 170 (Adani Power), Rs 4,180 (Titan), Rs 4,820 (Cummins India), Rs 2,250 (Mankind Pharma), and Rs 430 (Arvind Ltd).